Ninfa Candela to Crohn Disease
This is a "connection" page, showing publications Ninfa Candela has written about Crohn Disease.
Connection Strength
1.243
-
Cleveland NK, Ghosh S, Kathe N, Umashankar K, Mirchandani K, Hait A, Paul R, Candela N, Fan T, Rubin DT. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
Score: 0.217
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
Score: 0.216
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
Score: 0.215
-
Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Guerin A, Fan T. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States. Curr Med Res Opin. 2024 05; 40(5):877-885.
Score: 0.208
-
Vu M, Ghosh S, Umashankar K, Weber L, Landis C, Candela N, Chastek B. Comparison of surgery rates in biologic-na?ve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN. BMC Gastroenterol. 2023 Mar 25; 23(1):87.
Score: 0.194
-
Kaplan JL, Liu C, King EC, Bass JA, Patel AS, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti RB. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort. J Pediatr Gastroenterol Nutr. 2023 05 01; 76(5):566-575.
Score: 0.193